Perfil de usuario/a

Sergio Araujo

Resumen biográfico A few of the new therapies are already well advanced. They have already passed clinical trials and are in the approval procedure. However, the extent to which they have a real chance to benefit from the patients is open: this depends seborrheic dermatitis and hair loss on the cost carriers. The scientists are concerned, however, that the probably "expensive" drugs bring real economic benefits because they rehabilitate chronic patients in the long term. As long as the health insurance companies have to look only at the drug costs, the resistance to the drugs will be great. "The solution to this dilemma may therefore require a change in the societal view of the costs and benefits of the therapy," says Professor Prinz.

In Martin Schneider's realm, the computer and four letters: A, G, T, and C. Four letters in which a large part of the future lies between Schneider's employer, Schering AG, and which makes man what he is. They are the four basic building blocks of the 40,000 to 80,000 human genes and are called adenine, guanine, thymine and cytosine. Schneider is the company's top researcher. He and his colleagues want to know which genes play a significant role in certain diseases.

The market seems huge, but still very far away. For what Schneider and his colleagues are investigating, new medicines will be launched for sales in 2010 at the earliest. As long as it takes at least from the recognition of an important gene to the market launch.

"In 2020 or 2025, 20 to 30 percent of the drugs will be based on genetic research," estimates Berthold Baldus, head of the Office of Technology, who, among other things, will be able to acquire potential biotechnology partners for Schering AG. Schneider even estimates 50 percent. How the market actually develops is more of a philosophy.  seborrheic keratosis treatment There are no reliable studies. Approximately 80 percent of all diseases are currently considered not to be effectively treatable, including stroke and Alzheimer's disease. Schneider and Baldus see additional market potential here.

The pharma market has been growing steadily in recent years. Between 1994 and 1999, sales in Germany alone rose from 26.6 billion to 33.6 billion DM - the trend continues to rise. The world market last year, according to estimates by the Institute for Medical Statistics, had a volume of around 337.2 billion dollars (about 790 billion DM). For 2004 the institute expects 500 billion dollars.

In order to be ahead in the coming years, Schering has been developing the Research Area Functional Genome Analysis and Bioinformatics for three years. Schneider and his 30 employees systematically research the function of which human genes have. They do not have to study every 40,000 to 80,000 genes, only ten to 20 percent are currently considered interesting for the pharmaceutical industry, as Baldwin says. In some of the genes the function can be technically suppressed today, important for the treatment of tumors, for example. It is likely that a lot of genes are of interest to medicine, says Baldus.

The structure of the individual genes, ie the order in which the As, Gs, Ts and Cs are related, is widely known and stored in databases, for example in the Human Genome Project,  seborrheic dermatitis and hair loss a worldwide state funded research project or the US company Celera Genomics. However, not what the genes mean. "We have a lot of phrases, but they are totally spoiled and incomprehensible," says Schneider.

Esta publicación hace parte del Sistema de Revistas de la Universidad de Antioquia
¿Quieres aprender a usar el Open Journal system? Ingresa al Curso virtual
Este sistema es administrado por el Programa Integración de Tecnologías a la Docencia
Universidad de Antioquia
Powered by Public Knowledge Project